Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1 ...
3hon MSN
The National Hurricane Center is monitoring Potential Tropical Cyclone 19, which could impact Florida sometime next week | ...
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback